Compare Enveric Biosciences Inc (ENVB) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Illumina, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.59 (market cap $6.20M), while Illumina, Inc. trades at $191.59 (market cap $29.12B). The key difference: Illumina, Inc. is far larger — about 4696.8× Enveric Biosciences Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | ILMN | |
|---|---|---|
Market Cap | $6.20M | $29.12B |
Sector | Health | Health |
52-Week High | $17.40 | $205.10 |
52-Week Low | $1.27 | $91.00 |
Enterprise Value | $1.30M | $30.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.56, up 1.3% on the day, with a bullish technical signal from moving averages and strong analyst support (75% buy ratings). The company reported four consecutive quarterly earnings beats in 2025, including a positive EPS of $0.85 in Q4, while recent news highlights progress in preclinical studies for its non-hallucinogenic psychiatric drug candidate EB-003.
Despite operational losses and negative ROE/ROA, ENVB's consistent earnings surprises and advancing pipeline present speculative growth potential. Key risks include cash burn, clinical trial outcomes, and regulatory hurdles, requiring careful risk assessment by investors.
Illumina (ILMN) trades at $191.32, down 0.25% on the day, with a bullish earnings trend after beating Q2 2026 estimates. The stock shows strong profitability with a net margin of 18.34% and positive cash flow, though technical indicators signal near-term bearish pressure. Recent news highlights institutional buying and AI partnerships boosting growth prospects.
Outlook remains positive with a consensus price target of $201.58, offering ~5% upside, supported by solid fundamentals and analyst optimism. Risks include high valuation multiples and competitive pressures in genomics. The stock presents a growth opportunity with manageable near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
